COLL logo

COLLEGIUM PHARMACEUTICAL INC

COLLNASDAQ
πŸ† #2475 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track COLL
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$768M
Small Cap
πŸ“ˆRevenue Growth (YoY)
23.6%
Healthy
πŸ“ŠGross Margin
59.0%
Healthy
πŸ’΅FCF Margin
41.3%
Strong
βš–οΈP/S Ratio
0.9x
Cheap
Otter Score
76
Strong
No chart data available for COLL.

Trading Snapshot

Day Range
β€”
52-Week Range
$21.43 – $50.79
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
31.1M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$781M
Last Q Revenue
$216M
P/E Ratio
20.3
P/S Ratio
0.9x
EPS (TTM)
$1.20
Dividend Yield
0.00%
Dilution (1yr)
βˆ’1.0%
COLL logo

COLLEGIUM PHARMACEUTICAL INC

COLL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$781Mβ–² +23.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
59.3%β–Ό βˆ’0.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$187Mβ–² +10.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$328Mβ–² +61.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
39.7Mβ–Ό βˆ’1.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$689Mβ–² +$99M YoY
StockOtter Β· stockotter.space

About COLLEGIUM PHARMACEUTICAL INC

Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100
Analyst data unavailable.

Latest News & Updates

News unavailable.